Chitosan nanoparticles for mucosal and needle-free vaccination Authors: Changchun Chen, Cheng Zhang, Shanyuan Zhu, Shinuo Cao Published: 2026 ABSTRACT AbstractChitosan nanoparticles are emerging as versatile vaccine carriers that enhance antigen stability, improve mucosal delivery, and strengthen immune activation. This review synthesizes advances in their biological functions, chemical engineering, fabrication, and performance across inactivated, subunit, and nucleic acid vaccines. It defines structure function principles that guide rational design for thermostable and effective immunization, highlighting the promise of needle free mucosal vaccination for scalable use across diverse settings.Subject terms: Biotechnology, Drug discovery, Immunology, Materials science, Nanoscience and technology Introduction Vaccines remain the most effective intervention for controlling infectious diseases; however, conventional delivery systems are often limited by poor antigen stability, stringent cold-chain requirements, and suboptimal induction of mucosal immunity1–4. These hurdles, particularly acute in global health scenarios, necessitate the development of next-generation delivery platforms. Chitosan (CS), a natural cationic polysaccharide derived from chitin, has emerged as a preeminent biomaterial for overcoming these barriers, bridging the gap between pharmaceutical engineering and robust immunological efficacy. The primary advantage of CS lies in its exceptional biological versatility, which is inherently tunable through its degree of deacetylation (DDA) and molecular weight. By modulating these parameters, the density of free amino groups can be precisely adjusted to optimize the polymer’s charge density, mucoadhesiveness, and stability5–9. This cationic nature allows CS to form stable polyelectrolyte complexes with negatively charged antigens and mucosal surfaces, while its structural homology to bacterial peptidoglycans ensures enzymatic degradation into non-toxic metabolites, providing a superior safety profile for in vivo applications10,11. Recent advancements in nanotechnology have further amplified these inherent properties, positioning chitosan nanoparticles (CS-NPs) as transformative vaccine adjuvants and delivery vehicles12,13. By encapsulating delicate cargos, CS-NPs can stabilize antigens and prolong release kinetics, and some formulations have been reported to facilitate transport across biological barriers through mechanisms such as prolonged epithelial residence, tight-junction redistribution in selected cell models, and M-cell-associated transcytosis, which may support mucosal and systemic immune responses14,15. These nanoparticle platforms have already demonstrated high efficacy across diverse vaccine modalities, including viral (e.g., influenza, COVID-19), bacterial (e.g., tuberculosis), and therapeutic cancer vaccines1,16,17. However, it should be noted that no chitosan nanoparticle-based vaccine has yet received clinical approval, and the translation of these promising preclinical findings into licensed products remains an active area of investigation, with key challenges including scalability, batch-to-batch consistency, and regulatory standardization. Despite these rapid technological strides, a systematic synthesis of the design principles governing these carriers is essential for successful clinical translation. While several prior reviews have addressed individual aspects of chitosan in vaccine delivery, such as its adjuvant properties, general nanoparticle drug delivery applications, or chemical derivative preparation, a comprehensive and integrated analysis linking chitosan’s intrinsic biological activities, immunomodulatory signaling mechanisms (specifically the cGAS-STING and NLRP3 inflammasome pathways), advanced chemical modifications, and diverse fabrication methodologies within a unified structure function framework for vaccine design has been lacking. Furthermore, existing reviews have not systematically compared the performance of CS-NPs across all three major antigen modalities (inactivated, recombinant subunit, and nucleic acid vaccines) and all three mucosal delivery routes (nasal, oral, and pulmonary) in a single work. This review addresses these gaps by providing a comprehensive analysis of the preparation methods, chemical modifications, and immunomodulatory mechanisms of chitosan, with a specific focus on the latest breakthroughs in CS-NP-based vaccine delivery. By establishing clear structure-function relationships that connect chemical design to immunological outcomes, this study provides a robust theoretical foundation for the rational design of advanced immunization platforms. This review primarily examines mucosal immunization routes (nasal, oral, and pulmonary) that utilize chitosan’s mucoadhesive properties. However, chitosan nanoparticles are also being incorporated into other needle-free platforms, such as dissolving microneedle patches and transdermal nanocomplexes. These innovations exploit chitosan’s film-forming ability, biodegradability, and adjuvant-associated properties, and in some systems have been used to support minimally invasive antigen delivery to skin dendritic cells. Functional advantages of chitosan’s biological activities in vaccine delivery Chitosan nanoparticles exhibit excellent biocompatibility, antimicrobial, antioxidant, and antitumor activities due to their cationic nature, enzymatic degradability, and ability to modulate biological environments18–20. These multifunctional properties enhance mucosal adhesion, antigen stability, and immune stimulation, making them ideal candidates for vaccine delivery systems21. Biocompatibility and degradation kinetics of chitosan The clinical viability of chitosan-based vaccine carriers is primarily rooted in their exceptional biocompatibility, which arises from their structural homology with endogenous polysaccharides and predictable degradation kinetics. CS exhibits minimal systemic immunogenicity because its molecular structure closely mimics glycosaminoglycans found in mammalian extracellular matrices, facilitating seamless integration with host biological systems22. From a safety perspective, the metabolic fate and degradation profile of chitosan are well-characterized. In vivo, CS is primarily enzymatically degraded by lysozyme, which is present in various human body fluids at concentrations of 4–13 mg/L in serum and up to 450–1230 mg/L in tears23. This degradation cleaves β-(1,4)-glycosidic bonds, yielding glucosamine and N-acetylglucosamine, which are directly integrated into hexosamine biosynthetic pathways and converted into glucose-6-phosphate for cellular energy metabolism, ensuring that the carrier leaves no toxic residues after antigen delivery23. Critically, the degradation rate is tunable through the DDA. Chitosan matrices with low DDA (52.6%) exhibit rapid degradation with a weight half-life of approximately 9.8 days, whereas highly deacetylated forms (DDA > 71.7%) demonstrate weight half-lives exceeding 84 days under lysozymic conditions in vitro24. At the nanoparticle level, CS-TPP nanoparticles prepared with a higher degree of acetylation (DA 42%) showed a 40% decrease in particle diameter within 4 days of lysozyme exposure, while their highly deacetylated counterparts (DA 17%) remained essentially intact after 7 days25. In vivo, glutaraldehyde-crosslinked chitosan microspheres degraded into loose, porous structures within 12 weeks of intramuscular implantation, whereas genipin-crosslinked microspheres showed no significant degradation even after 20 weeks, demonstrating that the crosslinking strategy profoundly influences the in vivo degradation timeline25. Overall, degradation of chitosan implants occurs over a range of days to months depending on formulation parameters6. Despite their advantages, chitosan-based vaccine carriers face key challenges. Variability in chitosan’s raw material, due to different chitin sources and processing, causes inconsistencies in molecular weight, degree of deacetylation, and protein content, affecting nanoparticle reproducibility and immune response. Additionally, while chitosan is generally safe, high-molecular-weight chitosan ( > 300 kDa) can be cytotoxic and cause dose-dependent hemolysis, posing risks for systemic use. Highly deacetylated chitosan (DDA > 90%) can trigger a stronger inflammatory response in lung tissues than moderately deacetylated forms, affecting the safety of inhaled vaccines. Additionally, unmodified chitosan’s poor solubility at physiological pH requires acidic conditions for dissolution, risking the stability of pH-sensitive antigens. The regulatory framework for chitosan-based nanomedicines is still developing, with no unified quality standards, complicating clinical translation and approval. To advance chitosan nanoparticles from preclinical studies to clinical use, it’s crucial to establish standardized sourcing, thorough physicochemical characterization, and detailed tissue-specific toxicity assessments. Antibacterial properties of chitosan The inherent antibacterial properties of chitosan confer a self-protective capability to vaccine formulations, thereby ensuring antigen stability and preserving a sterile microenvironment at the site of administration20,26,27. This broad-spectrum antibacterial activity operates through three principal mechanisms. Initially, at physiological pH, the protonated amino groups of chitosan participate in electrostatic interactions with anionic components on bacterial surfaces, including lipopolysaccharides in Gram-negative bacteria and teichoic acids in Gram-positive bacteria. This interaction damages the membrane, causing essential metabolite leakage and bacterial death in 2 to 4 h. Additionally, chitosan’s amino and hydroxyl groups bind essential divalent cations (Fe²⁺, Mg²⁺, Ca²⁺), inhibiting bacterial enzymes and safeguarding co-delivered antigens from degradation. Lastly, chitosan disrupts extracellular polymeric substance matrices, reducing biofilm biomass and preventing infections that could impair the immune response28. The bactericidal selectivity is due to the distinct membrane structures of prokaryotes and eukaryotes. Bacterial membranes, rich in negatively charged phospholipids, attract cationic chitosan, while mammalian cell membranes, mainly composed of zwitterionic phospholipids with neutral charge, are less affected by chitosan disruption29,30. Cholesterol in mammalian membranes increases their rigidity and resistance to permeabilization. This charge-dependent selectivity allows chitosan-based vaccine carriers to prevent microbial contamination while minimizing cytotoxicity to host tissues, maintaining antigen integrity and tissue compatibility at the vaccination site. Redox-modulating properties of chitosan and their dual role in vaccine delivery Reactive oxygen species (ROS) play a paradoxical yet indispensable role in vaccine-induced immunity. As depicted in Fig. 1, regulated ROS generation has been reported in some CS-NP systems to be associated with mitochondrial perturbation and cytosolic DNA release, which may contribute to cGAS-STING pathway engagement and NLRP3 inflammasome assembly31–34. However, excessive ROS accumulation beyond this immunostimulatory threshold leads to oxidative degradation of redox-sensitive antigens and apoptotic tissue damage at the administration site, both of which impair productive immune priming32,35. Depending on formulation and experimental context, CS-NPs may act as redox modulators rather than indiscriminate antioxidants, helping maintain oxidative conditions compatible with innate immune signaling. The hydroxyl and amino groups on the chitosan backbone neutralize excess radicals through controlled radical-scavenging reactions, preserving basal ROS levels to support danger signal transduction36–38. Chemical modifications further enhance this capacity: EGCG-grafted chitosan and astaxanthin-loaded chitosan carriers demonstrate superior radical scavenging while protecting oxidation-sensitive cargos without compromising inflammasome priming39,40. Collectively, these studies suggest that some CS-NP formulations may help establish a spatiotemporally regulated redox microenvironment that supports a transient ROS burst and downstream induction of IL-1β, IL-18, and type I interferon-related responses. They prevent the accumulation of ROS beyond cytotoxic levels32,35. Schematic of three interconnected innate immune signaling pathways activated by chitosan nanoparticles (CS-NPs) in an antigen-presenting cell (APC). Panel 1 (left): Endo-lysosomal stress and antigen delivery. After endocytic uptake, CS-NPs go to endo-lysosomes, where chitosan’s amine group protonation causes the proton sponge effect. This leads to endosomal swelling, membrane rupture, and antigen release into the cytosol. Meanwhile, lysosomal rupture releases cathepsin B and chitosan chains, providing secondary danger signals. Panel 2 (center): NLRP3 inflammasome activation. Endo-lysosomal disruption causes cytosolic stress and ROS, triggering NLRP3 inflammasome assembly. It converts pro-IL-1β and pro-IL-18 into active forms. Also, phosphorylated IRF3 moves to the nucleus, driving type I interferon transcription. Panel 3 (right): cGAS-STING and NF-κB axes. Cytosolic stress causes mitochondrial perturbation and mtDNA release, sensed by cGAS. cGAS synthesizes cGAMP, activating STING on the ER. Activated STING moves to the Golgi, recruiting TBK1, which phosphorylates IRF3 and activates NF-κB/AP-1. These factors drive pro -inflammatory cytokine production. Secreted type I IFNs act via the IFNAR-JAK/STAT pathway to induce ISGs. Overall, this figure shows CS-NPs are multifaceted immunostimulators engaging multiple pathways, bridging innate and adaptive immunity through cytokine release. Chitosan nanoparticles as a multifunctional platform for cancer vaccine delivery Chitosan nanoparticles constitute an effective cancer vaccine delivery platform, integrating direct cytotoxic effects with systemic immune activation, while simultaneously enhancing the therapeutic index through improved solubility and stability of tumor associated antigens and reduced off-target toxicity38,41–43. Key advantages include their capacity for synergistic co-delivery of chemotherapeutic drugs and immunostimulatory agents, triggering antitumor effects and reversing tumor-induced immunosuppression with robust T-cell recruitment43. The functionalizability of chitosan also allows incorporation of targeting ligands such as folic acid, which in selected systems has been used to bias payload delivery toward tumor cells or antigen-presenting cells and may improve cellular uptake and antigen cross-presentation44,45. Chitosan nanoparticles exhibit pH-sensitive, stimuli-responsive properties within the acidic tumor microenvironment, enabling controlled, site-specific release of vaccine cargo and maximizing local immunomodulator concentrations. Additionally, some chitosan-based formulations have been reported to induce regulated ROS levels that may contribute to immunogenic cell death in cancer cells, with subsequent release of endogenous danger signals that could further amplify vaccine-induced immune responses46–49. Immunomodulatory effects of chitosan Chitosan has been reported to engage multiple innate immune signaling cascades in dendritic cells and macrophages in selected experimental systems, thereby influencing downstream adaptive immunity. This section provides a mechanistic dissection of three interconnected axes illustrated in Fig. 1: endo-lysosomal stress and antigen delivery, NLRP3 inflammasome activation, and the cGAS-STING/NF-κB signaling axes50–52. Endo-lysosomal stress, endosomal escape, and antigen delivery CS-NPs are internalized by antigen-presenting cells (APCs) via clathrin-mediated endocytosis, macropinocytosis, and receptor-mediated uptake driven by electrostatic interactions between cationic particles and anionic membrane proteoglycans53,54. Within the acidifying environment of the endo-lysosomal compartment, the primary amino groups of chitosan undergo significant protonation. In acidic endo-lysosomal compartments, protonation of chitosan amino groups has been proposed to promote ion and water influx, which in some systems may contribute to endosomal swelling and partial membrane destabilization55,56 (Fig. 1). This disruption results in two significant immunological implications. It liberates encapsulated antigens into the cytosol for proteasomal processing and MHC-I cross-presentation, enabling the priming of antigen-specific CD8⁺ cytotoxic T lymphocytes essential for combating intracellular pathogens and cancer57,58. In some experimental systems, release of cathepsin B, ROS, and mitochondrial DNA into the cytoplasm has been associated with downstream activation of NLRP3 inflammasome signaling and cGAS-STING pathway components. These observations suggest a potential link between intracellular antigen trafficking and innate immune activation in selected chitosan-based systems34. Activation of the NLRP3 inflammasome pathway Endo-lysosomal destabilization has been reported as one upstream signal associated with NLRP3 inflammasome activation in selected chitosan-based formulations (Fig. 1). Activation occurs through a two-signal model: Priming is mediated by the NF-κB-dependent transcriptional upregulation of NLRP3, pro-IL-1β, and pro-IL-18 upon the initial recognition of chitosan by receptors. In these systems, cytosolic cathepsin B release, mitochondrial ROS generation, and potassium efflux following lysosomal disruption have been proposed to contribute to NLRP3 oligomerization, ASC speck formation, and pro-caspase-1 processing34,59. Active caspase-1 catalyzes the conversion of pro-IL-1β and pro-IL-18 into their biologically active forms. IL-1β is broadly implicated in immune cell recruitment, Th17-associated differentiation, and T-cell co-stimulation, and these effects may contribute to the adjuvant activity observed in some CS-based systems. In conjunction with IL-12, IL-18 may support Th1-associated polarization and IFN-γ production by T cells and NK cells, thereby linking innate and adaptive immune responses in systems where inflammasome activation is observed33,34. Several studies suggest that higher DDA may increase protonation capacity and be associated with stronger inflammasome-related responses, whereas three-dimensional chitosan scaffolds may moderate NLRP3 signaling under prolonged delivery conditions34,59,60. Lymph node targeting and antigen-presenting cell engagement by chitosan nanoparticles Efficient antigen delivery to draining lymph nodes (dLNs) and uptake by resident APCs including dendritic cells, macrophages, and follicular dendritic cells, is central to vaccine efficacy, as lymph nodes are the primary sites where naïve T and B cells initiate adaptive immunity. Depending on particle size, surface charge, and formulation design, some CS-NPs have been reported to access afferent lymphatics and show greater lymph node accumulation than soluble antigen controls. The particulate properties of CS-NPs may facilitate APC uptake through macropinocytosis and receptor-mediated endocytosis in some systems; for example, carboxymethyl chitosan nanocapsules increased APC uptake of HBsAg, and chitosan-heparin nanovaccines were associated with enhanced DC activation in chronic HBV models61,62. Surface functionalization can further improve targeting in specific systems; for example, mannose-conjugated CS-NPs have shown enhanced biodistribution to nasal-associated lymphoid tissue and increased dendritic cell uptake in selected intranasal and cancer vaccine models58,63. The chitosan matrix additionally provides sustained antigen release to follicular DCs and germinal center B cells, promoting high-affinity antibody generation, as shown by N-2-HACC-Al nano-adjuvants in porcine epidemic diarrhea virus models64. For mucosal vaccination, CS-NPs extend this paradigm to MALT, where mucoadhesion and tight junction modulation facilitate antigen translocation to NALT, GALT, and BALT, enabling simultaneous secretory IgA and systemic IgG responses, as demonstrated against Chlamydia psittaci65 and Salmonella Enteritidis66. Collectively, these findings suggest that lymph node targeting can be improved through optimization of CS-NP size, charge, and ligand decoration, although the magnitude of this effect remains formulation and model dependent. Activation of the cGAS-STING and NF-κB/AP-1 signaling axes Activation of the cGAS-STING signaling pathway has been reported for selected CS-NP formulations and experimental systems (Fig. 1). In some experimental settings, disruption of endo-lysosomal compartments has been associated with mitochondrial perturbation and subsequent release of mitochondrial DNA into the cytoplasm. Here, the cyclic GMP-AMP synthase (cGAS) sensor detects mtDNA and catalyzes the production of the second messenger 2'3’-cyclic GMP-AMP (cGAMP) from ATP and GTP. cGAMP subsequently binds to the stimulator of interferon genes (STING) located on the endoplasmic reticulum, inducing a conformational change and facilitating its translocation to the Golgi apparatus. Within the Golgi, STING recruits and activates TANK-binding kinase 1 (TBK1), which in turn phosphorylates interferon regulatory factor 3 (IRF3). The phosphorylated IRF3 (P-IRF3) forms dimers and translocates to the nucleus, where it promotes the transcription of type I interferons (IFN-α/β) via the IFNB1 promoter33,52,67. The secreted type I interferons engage the interferon-alpha/beta receptor (IFNAR), activating the JAK-STAT signaling cascade and inducing the expression of interferon-stimulated genes (ISGs). This cascade establishes antiviral states, enhances the expression of major histocompatibility complex class I (MHC-I), promotes the maturation of DCs by upregulating CD80, CD86, and CD40, and facilitates the cross-priming of CD8⁺ T cells. Carroll et al. provided important evidence that, in their experimental system, chitosan adjuvanticity was closely linked to STING-mediated type I interferon induction67. In these contexts, STING and TBK1 activation, together with upstream receptor signaling, may also contribute to NF-κB/AP-1 activation and the induction of TNF-α, IL-6, and IL-1233,52,68. TNF-α facilitates the migration of APCs to draining lymph nodes; IL-6 induces the differentiation of B cells into plasma cells and supports the generation of T follicular helper (Tfh) cells; IL-12, in conjunction with IL-18, promotes T helper 1 (Th1) cell polarization and the production of interferon-gamma (IFN-γ). The degree of NF-κB/AP-1 activation is contingent upon molecular weight and the presence of DDA, offering an additional parameter for the rational design of adjuvants60,68. Role of chitosan in dendritic cell and macrophage activation The synchronized activation of endo-lysosomal escape, NLRP3, cGAS-STING, and NF-κB/AP-1 signaling pathways collectively facilitates the functional maturation of dendritic cells and macrophages. In these settings, DCs may acquire a more mature phenotype, characterized by increased expression of co-stimulatory molecules, greater cytokine secretion, and improved cross-presentation capacity53,54. Additionally, the mucoadhesive properties of chitosan can extend vaccine residence time at mucosal surfaces and, in some models, have been associated with enhanced uptake by sub-epithelial DCs and with both secretory IgA and Th1-biased systemic responses69,70. In macrophages, activation of cGAS-STING and NF-κB/AP-1 signaling has been associated with production of IL-12, TNF-α, and IL-6, which may support M1-like polarization and Th1-biased responses33,52,68. The extent of acetylation appears to modulate these immune responses, with increased deacetylation often being associated with stronger pro-inflammatory activation, whereas higher acetylation may yield more moderate immune profiles60,71. Some CS-NP formulations appear to support stronger acute inflammatory activation, whereas scaffold forms of chitosan have been reported to moderate NLRP3-related responses during prolonged delivery34,59. Integrated model of chitosan-mediated innate immune activation The immunomodulatory effects of chitosan can be interpreted through three mechanistically interconnected pathways that have been described in selected studies (Fig. 1). One proposed initiating event is escape or destabilization of endo-lysosomal compartments, which may facilitate antigen access for cross-presentation and generate DAMPs associated with NLRP3 inflammasome and cGAS-STING pathway activation. Activation of the NLRP3 inflammasome leads to the production of IL-1β and IL-18, promoting Th1 and Th17 cell polarization. Concurrently, the cGAS-STING pathway induces the production of type I interferons, which are crucial for cytotoxic T lymphocyte (CTL) priming and the establishment of antiviral states. Additionally, the NF-κB/AP-1 pathway contributes to the creation of a pro-inflammatory cytokine environment, facilitating the recruitment of immune cells. Taken together, these pathways may help explain why some chitosan-based systems show enhanced cross-presentation and combined humoral, cellular, and mucosal immune responses, although the magnitude of these effects remains formulation-dependent33,72. Advanced chitosan derivatives for targeted vaccine delivery As a versatile vaccine delivery platform, chitosan offers a unique linear polysaccharide structure composed of β-(1-4)-linked D-glucosamine and N-acetyl-D-glucosamine units, which facilitates the encapsulation and stabilization of diverse antigens. Its chemical architecture provides abundant reactive sites, specifically primary amines at C2 and hydroxyl groups at C3 and C6, with a reactivity hierarchy of C2-NH₂ > C6-OH > C3-OH63. These reactive sites enable precise chemical modifications, converting the parent polymer into a diverse library of tailored derivatives (Fig. 2). Such modifications tailor the physicochemical properties of the carrier, including enhanced aqueous solubility and pH-responsive release, and in some formulations may improve interactions with professional antigen-presenting cells73–75. By establishing these structure-function relationships, researchers can rationally design vaccine delivery systems with predictable kinetics and specialized immunomodulatory functions. Ultimately, these derivatives serve as optimal, biocompatible, and biodegradable platforms for next-generation vaccines, capable of addressing complex therapeutic requirements while maintaining high safety profiles76–78. Overview of chemical modification strategies for chitosan backbone and their vaccine delivery applications. The central ring shows native chitosan, a linear polysaccharide of β-(1 → 4)-linked GlcN and GlcNAc units, with three reactive sites (C2-NH₂, C6-OH, C3-OH) and reactivity hierarchy of C2-NH₂ > C6-OH > C3-OH. Radiating from the core, each sector represents a modification strategy: quaternization (for nucleic acid vaccine delivery), carboxymethylation (for protein vaccine delivery), alkylation (for oral vaccine delivery), acylation (for nasal vaccine delivery), Schiff base formation (for pH-responsive delivery), graft copolymerization (for combination and polyvalent vaccines), esterification (for DNA vaccine delivery), and etherification (for stability and drug delivery). The outer periphery shows vaccine delivery applications like cancer, DNA, drug, and respiratory mucosal delivery. This figure shows that chitosan’s reactive groups allow rational engineering of derivatives for specific antigens, routes, and immunological goals. Quaternization for enhanced nucleic acid delivery Quaternization significantly improves chitosan’s performance as a nucleic acid vaccine carrier by conferring permanent cationic charge and pH-independent water solubility, which are essential for efficient antigen encoding and delivery. The introduction of quaternary ammonium groups, such as in N-trimethyl chitosan (TMC) and N-(2-hydroxypropyl)-3-trimethyl chitosan (HTCC), facilitates superior complexation with DNA or mRNA into stable polyplexes (typically 160–280 nm)79,80. These derivatives can protect genetic cargo from enzymatic degradation and, in some formulations, have been associated with enhanced membrane interactions and improved endosomal escape, which may support sustained gene expression and immune activation81. Recent applications highlight the potency of this modification. HTCC-formulated mRNA vaccines have demonstrated up to a 127-fold increase in transfection efficiency over naked mRNA, driven by improved cellular internalization and optimal zeta potentials ( + 12.5 to +18.7 mV)80. In HPV16 E7-targeted therapy, quaternized CS-NPs elicited a 5.8-fold enhancement in CD8 + T cell responses and achieved 85% tumor protection compared to unmodified chitosan80. Therefore, higher degrees of quaternization correlate with increased antioxidant activity and charge density, further stabilizing DNA vaccines and inducing powerful systemic responses, particularly for next-generation influenza vaccines82,83. Carboxymethylation for enhanced protein and viral vaccine delivery Carboxymethylation transforms chitosan into an ideal delivery vehicle for sensitive protein and viral antigens by imparting physiological pH solubility and superior biocompatibility while maintaining potent adjuvant properties84,85. The introduction of anionic carboxyl groups in Carboxymethyl Chitosan (CMC) facilitates the encapsulation of antigens under mild conditions, protecting them from proteolytic degradation and reducing immunotoxicity21,61,86. CMC-based systems have been reported to enhance both humoral and cellular immune responses, in part through improved antigen uptake by dendritic cells and associated increases in IgG, sIgA, IFN-γ, and IL-6 in selected models79–82. CMC nanocapsules delivering Hepatitis B surface antigen achieved a 4.3-fold increase in uptake by antigen-presenting cells61, while CMC-coated iron oxide nanoparticles used with H9N2 avian influenza vaccines markedly elevated antibody levels and Th1-polarized cellular responses87. These features position CMC as a premier platform for sustained immune stimulation and the delivery of complex protein-based therapeutics. Alkylation as a strategy for vaccine enhancement Alkylation significantly boosts the potential of chitosan as a vaccine delivery platform by integrating hydrophobic properties that improve membrane interactions and antibacterial activity. This modification creates a dual carrier-adjuvant system that maintains essential immunoregulatory functions80. A prominent example is N-2-Hydroxypropyl Trimethyl Ammonium Chloride Chitosan (N-2-HACC), which serves as a potent adjuvant. Research indicates that N-2-HACC markedly strengthens both humoral and cellular immune responses across various formulations, including vaccines for porcine epidemic diarrhea virus and porcine parvovirus80,88. The efficacy of these derivatives is further amplified when integrated into nanoparticle systems. Combining N-2-HACC with carboxymethyl chitosan (CMCS) nanoparticles enhances immunogenicity, triggering elevated levels of antibodies (IgG, IgG1, IgG2a, sIgA) and key cytokines (IL-6, IL-4, IFN-γ, and TNF-α)89. Furthermore, N-dodecyl chitosan improves the serum stability of peptide based vaccines with a critical factor for therapeutic efficacy90. Furthermore, chitosan-coated silica nanoparticles have proven effective for oral delivery, eliciting robust in vivo immune responses91. Acylation as a strategy for mucosal vaccine optimization Acylation introduces hydrophobic acyl chains onto the chitosan backbone via amide or ester bonds, converting it into an amphiphilic derivative with enhanced mucosal vaccine delivery capabilities55,92. The grafted acyl chains penetrate hydrophobic domains of mucin networks and associate with epithelial membrane phospholipids, creating a dual-anchoring mechanism that, combined with electrostatic interactions, prolongs antigen residence at mucosal surfaces. Acylation has been proposed in some studies to bias cellular uptake toward lipid raft-associated endocytosis in APCs, which may support MHC class I cross-presentation and enhanced CD8⁺ T-cell responses55,93. The amphiphilic derivatives spontaneously self-assemble into core-shell micelles, enabling co-encapsulation of hydrophobic antigens and adjuvants while maintaining colloidal stability and mucoadhesion93,94. Additionally, intermolecular hydrophobic associations between acyl chains enhance thermal stability, supporting cold-chain-independent vaccine development. These advantages have been reported in respiratory vaccine models, where acylated chitosan carriers were associated with stronger sIgA responses, prolonged NALT exposure, enhanced alveolar macrophage uptake, and broader mucosal and systemic immunity in selected influenza, pneumococcal, and COVID-19 studies55,92. Through acylation, chitosan can be developed into a platform with improved mucosal retention and, in some systems, enhanced APC engagement and immune activation, supporting the development of next-generation needle-free respiratory vaccines. Schiff base formation as a strategy for pH-sensitive vaccine delivery Schiff base formation enhances vaccine efficacy by providing pH-sensitive release mechanisms that allow for precise, controlled delivery of antigens within specific physiological environments. This approach utilizes the dynamic and reversible nature of Schiff base linkages, which undergo hydrolysis in response to pH fluctuations to trigger cargo release. In the development of smart vaccine delivery systems, Schiff base formation has emerged as a sophisticated strategy to achieve pH-sensitive antigen release and enhanced therapeutic stability. By leveraging the dynamic and reversible nature of Schiff base linkages, researchers have developed high efficiency composite hydrogels, such as those combining modified chitosan with oxidized sodium alginate that prevent premature leakage while ensuring rapid cargo release in acidic environments95. These advanced systems also offer unique functional advantages, including injectable and self-healing properties achieved through dual Schiff base and hydrogen bond networks96. Such smart platforms allow for precisely tunable release rates, significantly increasing cumulative release under acidic conditions compared to alkaline environments97. Ultimately, these pH-sensitive linkages protect delicate vaccine components during transport and facilitate targeted delivery within acidic endosomes or inflamed tissues, thereby maximizing the resulting immune response. Graft copolymerization as a platform for polyvalent and combination vaccines Graft copolymerization utilizes the three main reactive sites on the chitosan backbone: the C2 primary amine (–NH₂), the C3 hydroxyl (–OH), and the C6 primary hydroxyl (–OH), to covalently attach functional polymer chains. The general reactivity hierarchy of these sites is C2–NH₂ > C6–OH > C3–OH98. The C2 amine is the most nucleophilic site and is preferentially employed for initiating radical or ring-opening graft polymerization, enabling the attachment of cationic branches such as poly (acryloyloxy) ethyl trimethylammonium chloride to enhance solubility and immune cell recruitment99,100. Due to its reduced steric hindrance compared to the C3 position, the C6 hydroxyl group is preferentially utilized for the conjugation of hydrophilic polymers, particularly polyethylene glycol (PEG). This conjugation markedly enhances colloidal stability, extends systemic circulation, and increases the immunogenicity of complex antigens, including pneumococcal polysaccharides96,101. These multifunctional architectures facilitate the concurrent loading of diverse antigens with adjustable release kinetics, maintain prolonged antibody titers, enhance Th2-mediated immune responses, and improve antigen cross-presentation and cytotoxic T lymphocyte activity. Collectively, these attributes position grafted chitosan copolymers as an optimal platform for the development of highly efficacious polyvalent vaccines96,102–104. Esterification and hydrophilic modification for vaccine delivery Esterification via the introduction of phosphate and sulfate groups significantly enhances chitosan’s utility in DNA vaccine delivery by improving water solubility, nuclease protection, and nucleic acid binding affinity. These modifications overcome the inherent limitations of native chitosan, such as poor solubility at physiological pH and overly rigid ionic interactions with DNA. This strategy aligns with broader polymer chemistry principles where hydrophilic grafting optimizes functional performance for clinical use105–107. The strategic introduction of specific chemical groups has yielded several high-performance variants. The synthesis of N-quaternary ammonium-O-sulfobetaine-chitosan (Q3BCS) demonstrates that introducing charged groups can dramatically increase water solubility, from near 0% to 113% at neutral pH, while simultaneously boosting antibacterial activity and biocompatibility108. Conjugating hydrophilic tricine (containing a secondary amine) increases chitosan’s hydrophilicity and transfection efficiency, achieving results comparable to commercial agents like Lipofectamine™ 2000109. Modifying chitosan with secondary or tertiary amines, such as imidazole acetic acid (IAA), enhances both solubility and buffering capacity. These IAA-modified derivatives have shown a 100-fold increase in pDNA transfection efficiency over native chitosan, nearly matching the performance of polyethyleneimine (PEI)110. Collectively, these chemical modifications transform chitosan into a highly efficient, soluble, and biocompatible platform for the delivery of genetic vaccines. Etherification and stability enhancement for vaccine delivery Etherification of chitosan at its hydroxyl sites significantly improves the biopolymer’s water solubility and structural stability, providing a robust platform for the formulation of stable vaccine delivery systems (Table 1). While chitosan is prized for its biocompatibility and biodegradability, its practical use in vaccines is often hindered by poor solubility and environmental sensitivity. The introduction of ether bonds that highly stable in both acidic and alkaline conditions addresses these limitations, ensuring the integrity of the vaccine carrier across varying physiological pH levels111,112. By facilitating the delivery of active ingredients, the strategic application of etherification provides significant functional advantages: it enhances the bioavailability of poorly soluble compounds through improved dissolution rates113 and creates amphiphilic variants that serve as effective emulsifiers for oil-in-water adjuvant systems114,115. Furthermore, these modifications allow for the engineering of materials with tailored mechanical properties, such as increased flexibility and ductility, which are essential for advanced tissue engineering and controlled-release scaffolds114. Ultimately, etherification transforms chitosan into a more resilient and versatile material, capable of protecting sensitive vaccine components while providing the mechanical and chemical stability required for effective clinical application. Table 1Comparative analysis of chemical modifications of chitosan for vaccine delivery applicationsModification typeRepresentative derivativesKey structural changesFunctional enhancementsPrimary vaccine applicationsRepresentative outcomesQuaternization79–83N-trimethyl chitosan (TMC); N-(2-hydroxypropyl)-3-trimethyl chitosan (HTCC)Quaternary ammonium substitution at C2–NH2 (e.g., TMC/HTCC)Permanent cationic charge; pH-independent solubility; improved uptake/endosomal escapeDNA/mRNA vaccines; therapeutic HPV; influenza vaccinesUp to 127× higher transfection vs naked mRNA; 5.8× higher CD8+ response; 85% tumor protection (HPV16 E7)Carboxymethylation84–87O-Carboxymethyl chitosan (O-CMC); N-Carboxymethyl chitosan (N-CMC)Carboxymethyl substitution at C6–OH and/or C2–NH2 (O-/N-CMC)Physiological-pH solubility; mild antigen encapsulation; reduced immunotoxicityProtein/viral antigens (e.g., HBsAg); H9N2 AIV vaccines4.3× higher APC uptake (HBsAg); higher Th1-skewed responses; higher antibody titersAlkylation80,88–90N-2-Hydroxypropyl trimethyl ammonium chloride chitosan (N-2-HACC); N-dodecyl chitosanN-alkyl/hydrophobic substitution (often with cationic moieties)Enhanced membrane interaction; antimicrobial activity; carrier–adjuvant duality; improved serum stabilityPEDV vaccines; porcine parvovirus vaccines; peptide-based vaccinesHigher IgG/IgG subclasses and sIgA; higher IL-6/IL-4/IFN-γ/TNF-α; improved peptide vaccine stabilityAcylation55,92Acyl-chitosan derivatives (acetyl, propionyl, butyryl chains)Introduction of hydrophobic acyl chains via amide bond formationHigher thermal stability; prolonged mucosal residence; improved targeting/adhesionRespiratory viral vaccines; influenza vaccines; COVID-19 mucosal vaccines; pneumococcal vaccinesStrong mucosal sIgA; higher alveolar macrophage uptake; protection in respiratory challenge modelsSchiff Base Formation96,97Chitosan-aldehyde conjugates; chitosan-oxidized polysaccharide hydrogelsDynamic imine bond ( − CH = N − ) formation between amino groups and aldehydespH-responsive release; injectable/self-healing hydrogels; tunable degradationSmart vaccine delivery systems; pH-responsive antigen release platformsAcid-triggered release with reduced premature leakage; tunable release kineticsGraft Copolymerization96,98–104Chitosan-g-PEG; chitosan-g-poly(acryloyloxy)ethyl trimethylammonium chloride; chitosan-PLA compositesCovalent grafting of functional polymers onto chitosan backboneMultifunctional grafts; improved solubility/stability; enhanced immune cell recruitmentPolyvalent/combination vaccines; pneumococcal polysaccharide vaccines; chronic hepatitis B vaccines; influenza vaccinesSustained antibody titers; Th2 skewing; improved cross-presentation; strong CTL activityEsterification (Phosphorylation/Sulfation)105–110Phosphorylated chitosan; sulfated chitosan; N-quaternary ammonium-O-sulfobetaine-chitosan (Q3BCS)Introduction of phosphate ( − PO₄²⁻) or sulfate ( − SO₃⁻) groupsHigher water solubility; stronger nucleic-acid binding; improved buffering; nuclease protectionDNA vaccines; genetic vaccinesReported relative solubility: ~0% → 113% at neutral pH; ~100× higher pDNA transfection; comparable to Lipofectamine™ 2000Etherification111–115Hydroxyethyl chitosan; hydroxypropyl chitosan; carboxymethyl-hydroxyethyl chitosanIntroduction of ether bonds ( − C − O − C − ) at hydroxyl sitesHigher solubility and pH-stability; amphiphilicity; improved mechanical propertiesStable vaccine formulations; oil-in-water adjuvant emulsions; controlled-release scaffoldsImproved bioavailability; effective emulsification; tunable mechanics for controlled-release/scaffolds Comparative analysis of chemical modifications of chitosan for vaccine delivery applications Preparation methods of chitosan-based nanoparticles and their applications in vaccine delivery The preparation method of nanoparticles plays a crucial role in determining the physicochemical properties, stability, and immunological performance of chitosan-based vaccine delivery systems (Table 2). Different fabrication techniques offer distinct advantages and can be selected based on antigen type, route of administration, and clinical requirements. These methods enable precise control over particle size, surface charge, antigen loading, and release kinetics, thereby facilitating the rational design of vaccine formulations with improved stability, bioavailability, and immunogenicity. Table 2Representative preparation methods for chitosan-based nanoparticles in vaccine deliveryMethodKey featuresRepresentative vaccine modelsMain outcomesEmulsion cross-linkingDense particles, high structural stability, controlled releaseHepatitis B (HBsAg)Increased antibody titers, prolonged immune persistenceIonic cross-linkingMild aqueous preparation, broad antigen compatibility, high loading efficiencyInfluenza, Hepatitis B, COVID-19, Tuberculosis, FMDV (TNF-α-VLP), FMDV (Zn²⁺-coordinated iFMDV)Improved antigen stability, enhanced mucosal and systemic immunity, stronger B- and T-cell responsesSpray dryingDry powder formulation, scalable production, improved thermostabilityInfluenza, Pneumococcal, TuberculosisHigh loading efficiency, cold-chain reduction, suitability for pulmonary deliveryComplex coacervationPolyelectrolyte complex formation, solvent-free encapsulation, mucosal suitabilityNDV F-gene DNA vaccine, Salmonella Gallinarum, SARS-CoV intranasal DNA vaccineHigh encapsulation efficiency, increased IgG, sIgA, and IFN-γ, effective oral and intranasal immunizationPrecipitation / nanoprecipitationSmall particle size, narrow distribution, efficient cellular uptakeJEV, influenza, cancer vaccine modelsImproved mucosal delivery, enhanced dendritic-cell uptake, and transfection efficiencySelf-assemblyAmphiphilic core-shell nanostructures, mild preparation, co-loading capacityGroup A Streptococcus (KLH/lipoJ14), microbial antigen formulations, tumor-antigen vaccinesSustained release, strong IgG responses, balanced Th1/Th2 profile, immune activation in cancer modelsCovalent cross-linkingRobust network structure, pH stability, sustained antigen presentationSwine influenza, Hepatitis B, Pneumococcal vaccinesProlonged antibody persistence, enhanced memory responses, improved thermostability Representative preparation methods for chitosan-based nanoparticles in vaccine delivery Emulsion cross-linking methods The emulsion cross-linking method facilitates the synthesis of structurally dense CS-NPs through a water-in-oil (W/O) emulsion system. Typically, aqueous chitosan (1–2% w/v in acetic acid) is dispersed in an organic phase, such as toluene, using Span 80 (HLB 4.3) as a stabilizer116. Chemical stabilization of the droplets is achieved through cross-linking agents: glutaraldehyde (0.1–0.5% v/v) utilizes Schiff base formation, while genipin (0.1–0.5% v/v) proceeds via Michael addition. Notably, genipin offers superior biocompatibility, maintaining cell viability at 85–95% compared to the 60-70% observed with glutaraldehyde117. These resulting nanoparticles are characterized by a uniform size distribution (150–300 nm, PDI < 0.2) and high colloidal stability (zeta potential +30 to +50 mV). In HBV vaccine delivery, this platform has demonstrated significant potency, increasing anti-HBsAg IgG titers 4.8-fold compared to free antigens (p < 0.001) and extending antibody persistence to 36 weeks in murine models16. Recent microfluidic adaptations have further refined this process, reducing organic solvent consumption by 90% while maintaining high encapsulation efficiencies ( > 80%) for 24 kDa proteins118. Ionic cross-linking method The ionic cross-linking methodology, driven by electrostatic interactions between protonated chitosan and multivalent anions such as tripolyphosphate (TPP), is the predominant approach for synthesizing vaccine-loaded nanoparticles. This technique is favored for its mild processing conditions, which preserve the integrity of sensitive biologics119. By providing enhanced antigen stability, controlled release kinetics, and improved cellular uptake, ionic cross-linking addresses critical global vaccine accessibility challenges through superior thermostability and immunological efficacy118. This technique has demonstrated exceptional utility across diverse vaccine platforms, including influenza, hepatitis B, COVID-19, and tuberculosis formulations, with significant immunological advantages attributable to its mild processing conditions and high antigen loading capacity16,55,118,120. Beyond classical TPP-mediated gelation, related electrostatic and coordination-based strategies further expand the utility of this approach. Chitosan-TNF-α-VLP nanoparticles prepared via ionotropic gelation induced strong humoral and cellular immune responses against foot-and-mouth disease virus (FMDV) in mice, comparable to commercial vaccines; these nanoparticles also activated lymph node mast cells, highlighting their potential to stimulate both Th1 and Th2 pathways121. To further enhance antigen structural integrity, CS-NPs chelated with Zn²⁺ (CP-PEI-Zn) leverage histidine-histidine-Zn²⁺ coordination to bind inactivated FMDV (iFMDV). This metal-coordination method preserves antigen conformation more effectively than conventional electrostatic loading, leading to superior B cell activation, cytokine secretion, and memory T cell proliferation122. Spray drying method The spray drying method facilitates the large scale, stable production of chitosan based vaccine formulations, offering rapid processing, precise particle size control, and high product purity. By transforming liquid dispersions into dry powders, this technique produces vaccines that require no refrigeration, possess an extended shelf life, and support needle free administration, which attributes that are vital for mass immunization programs in resource limited regions. Kanojia et al. (2016) demonstrated that spray-dried influenza vaccine powders maintained their antigenic stability even after storage for 3 months at 60°C using a Design of Experiment approach to optimize process parameters. Spray-dried chitosan formulations for influenza, pneumococcal, and tuberculosis vaccines show over 99% protein antigen loading efficiency, eliminate cold-chain needs by maintaining immunogenicity for 90 days at room temperature, and are suitable for pulmonary delivery92,123. Complex coacervation method Complex coacervation leverages associative phase separation between oppositely charged polyelectrolytes, typically involving cationic chitosan and anionic polymers such as sodium alginate, carrageenan, or DNA, under meticulously controlled conditions of pH, temperature, and ionic strength. This process results in the formation of dense coacervate droplets capable of encapsulating antigens without the use of organic solvents or chemical cross-linkers124–127. This eco-friendly, solvent-free approach is ideal for delivering oral and mucosal vaccines in livestock and poultry, as it boosts gastrointestinal stability via a polyelectrolyte complex shell. The coacervation process is highly adaptable; altering the chitosan to counterpolymer mass ratio and solution pH allows control over particle size, encapsulation efficiency, and release kinetics14. In a specific application, Newcastle disease virus (NDV) F gene DNA vaccines encapsulated using chitosan-based complex coacervation yielded nanoparticles with an average diameter of 199.5 nm and an encapsulation efficiency of 98.37%. These nanoparticles significantly increased serum IgG, mucosal sIgA, and IFN-γ levels following both intramuscular and intranasal administration in chickens15,128. Chitosan-alginate coacervate microparticles have been used for oral delivery of a Salmonella Gallinarum vaccine, achieving over 60% encapsulation efficiency and effective protection, similar to subcutaneous methods129. Raghuwanshi et al. showed that biotinylated chitosan nanoparticles, enhanced with dendritic cell-targeting proteins, enable low-dose intranasal DNA vaccination against SARS-CoV, boosting mucosal IgA and systemic IgG responses130. These cases demonstrate that complex coacervation is a versatile method for creating antigen-loaded nanoparticles with high encapsulation and strong immunogenicity. Precipitation method Precipitation methodologies, including nanoprecipitation and coprecipitation, generate exceptionally small CS-NPs (20–100 nm) with narrow size distributions. These compact dimensions facilitate superior cellular uptake and transfection efficiency, making the method particularly effective for nucleic acid and viral vaccine delivery. These compact dimensions have been exploited across JEV, cancer, and influenza vaccine platforms, where precipitation-derived nanoparticles (65 ± 15 nm) facilitated efficient mucosal delivery and superior cellular uptake by dendritic cells compared to conventional formulations58,131,132. Self-assembly method The self-assembly of amphiphilic chitosan derivatives into core–shell nanostructures leverages non-covalent interactions-including hydrogen bonding, electrostatic forces, and hydrophobic interactions-to form functional nanoparticles under mild aqueous conditions without chemical cross-linkers93,94,133. Attaching hydrophobic groups like deoxycholic acid, oleic acid,cholesterol, or alkyl chains to the hydrophilic chitosan backbone forms amphiphilic conjugates that self-assemble into core-shell micelles or nanoparticles. The hydrophobic core stores antigens or adjuvants, while the cationic hydrophilic shell aids in mucoadhesion and cellular uptake14,93. Recent studies highlight the effectiveness of self-assembled chitosan nanoparticles in vaccines. Nevagi et al. (2022) created amphiphilic chitosan nanoparticles (ACNs) with arginine and oleic acid for Group A Streptococcus (GAS) vaccine delivery. These 220–240 nm core-shell particles encapsulated KLH protein and a B cell peptide epitope (lipoJ14), inducing strong IgG antibody responses in mice with a balanced Th1/Th2 profile and 65-80% opsonic activity against GAS strains, comparable to Freund’s complete adjuvant15. Oleoyl-modified carboxymethyl chitosan self-aggregates (157–397 nm, zeta potential +16 to +20 mV) demonstrated 52–63% loading efficiency for microbial antigens with sustained release over 40 h, presenting a promising platform for tuberculosis and bacterial vaccines. Zhang et al. (2023) reported that self-assembled chitosan-based nano-micelles activated cGAS-STING-associated signaling in dendritic cells and macrophages in their study. This resulted in strong type I interferon production, increased co-stimulatory molecules (CD80, CD86, MHC-II), and Th1-polarized immune responses when combined with tumor antigens, highlighting their dual role as delivery vehicles and immunological adjuvants in cancer vaccines52. Together, these findings indicate that self-assembled amphiphilic chitosan nanoparticles can function as effective vaccine carriers and may also influence immune responses in specific formulations. Covalent cross-linking method Covalent cross-linking using natural agents, such as genipin, yields CS-NPs with exceptional structural stability and precisely controlled release kinetics. Unlike physical interactions, covalent bonds create robust networks that remain insoluble across a wide pH range while retaining the ability to swell in aqueous media, ensuring the protection of antigens in challenging biological environments134. This methodology offers distinct immunological advantages, particularly for vaccines requiring sustained presentation and long-term memory. Oral and intranasal immunization studies confirm that cross-linked formulations afford superior neutralizing antibody persistence and memory T-cell formation compared to non-cross-linked alternatives, across diverse platforms including swine influenza, hepatitis B, and pneumococcal antigens92,118,135. Critically, the structural integrity of these particles is maintained in simulated nasal fluids, and lyophilized forms achieve remarkable thermostability, remaining potent for up to one month at 40 °C84. Key factors influencing the performance of chitosan nanoparticles The performance of CS-NP based vaccine delivery systems is determined by three main factors: chitosan’s intrinsic structural parameters, fabrication methodology, and formulation design for specific antigen-route combinations. Chitosan’s molecular weight (MW) and DDA are fundamental. Low MW chitosan ( < 10 kDa) gives smaller particles (80–130 nm) with better biosafety, while high MW chitosan ( > 80 kDa) yields larger particles ( > 300 nm) with stronger mucoadhesive capacity. Reducing MW from 213,000 to 10,000 decreases cellular uptake by 26%. Optimal charge density for antigen complexation needs 85-95% DDA, and lowering DDA from 88 to 46% reduces uptake by up to 41%. For pDNA delivery, encapsulation efficiency is directly proportional to DDA but inversely proportional to MW. The fabrication method has an independent and often dominant influence on nanoparticle performance. Different techniques using the same chitosan materials lead to different results. Ionic cross-linking produces 100–400 nm particles with good thermostability, nanoprecipitation generates 20–100 nm particles for better cellular uptake and transfection efficiency, spray drying offers long-term thermal stability, and covalent cross-linking with genipin provides pH-stable networks for sustained antigen presentation. Process-specific variables also modulate encapsulation efficiency, surface charge, and release kinetics. To maximize vaccine performance, size optimization is crucial to avoid reticuloendothelial system clearance ( > 100 nm) and renal elimination ( < 5 nm). In COVID-19 applications, specific-sized nanoparticles achieved optimal biodistribution and antibody responses. Optimized intranasal carriers enhanced cellular internalization. The rational design of CS-NP vaccines requires a multidimensional optimization strategy integrating material parameters, fabrication processes, and application-specific requirements. Quality control parameters and characterization methods Beyond optimizing MW, DDA, and particle size, the successful translation of CS-NP vaccine formulations demands rigorous quality control (QC) and comprehensive physicochemical characterization at every stage of development. Critical QC parameters include hydrodynamic diameter, polydispersity index (PDI), zeta potential, encapsulation efficiency (EE%), antigen loading capacity, residual solvent content, endotoxin levels, and sterility14,15. Dynamic light scattering (DLS) remains the gold standard for routine measurement of particle size distribution and PDI, while electrophoretic light scattering quantifies zeta potential as a predictor of colloidal stability; values exceeding ±30 mV are generally considered indicative of stable formulations. For morphological assessment, transmission electron microscopy (TEM) and scanning electron microscopy (SEM) provide direct visualization of nanoparticle shape, surface topology, and core-shell architecture, complemented by atomic force microscopy (AFM) for nanoscale surface roughness characterization. Encapsulation efficiency and antigen integrity are typically quantified via BCA or ELISA assays for protein antigens and agarose gel electrophoresis or quantitative PCR for nucleic acid cargos80,105. Fourier-transform infrared spectroscopy (FT-IR) and differential scanning calorimetry (DSC) serve as essential tools for confirming successful chemical modification, verifying cross-linking reactions, and assessing the thermal stability of encapsulated antigens84. Furthermore, gel permeation chromatography (GPC) and viscometry are employed to determine MW and MW distribution of the chitosan starting material, while potentiometric titration and first-derivative UV spectroscopy enable precise DDA quantification-both parameters that must be rigorously controlled to ensure batch consistency. Collectively, these characterization methods form a comprehensive analytical framework that enables systematic quality assessment of CS-NP vaccine formulations from laboratory development through to regulatory submission. Thermostability mechanisms and formulation strategies for cold chain independent CS-NP vaccines A consistently highlighted benefit in this review is the thermostability of chitosan nanoparticle (CS-NP)-based vaccine formulations. Nevertheless, the molecular mechanisms and formulation strategies responsible for this property warrant comprehensive investigation. At the molecular level, chitosan enhances antigen thermostabilization through three interrelated mechanisms. Firstly, electrostatic encapsulation occurs as the dense cationic charge network, formed by protonated amino groups, physically entraps and immobilizes protein or nucleic acid antigens within the polymeric matrix. This entrapment restricts the conformational flexibility that typically leads to thermal denaturation and aggregation14. During drying, chitosan’s hydroxyl and amino groups form hydrogen bonds with antigen surfaces, replacing the hydration shell lost with water removal, similar to trehalose and sucrose’s “water replacement hypothesis.” Additionally, chitosan creates a rigid matrix with a high glass transition temperature when dried, limiting molecular movement and preventing chemical degradation, thus preserving antigen potency at high temperatures. These stabilization properties are utilized in two main drying strategies. Spray drying turns liquid CS-NP dispersions into dry powder vaccines by rapidly evaporating the solvent. This process keeps the antigen’s temperature below the wet-bulb temperature, preserving its structure despite high air temperatures. Evidence shows that spray-dried influenza vaccines with chitosan carriers remained stable after 3 months at 60 °C, and spray-dried tuberculosis vaccines retained immunogenicity for 90 days at room temperature, unlike their liquid counterparts. Lyophilization, or freeze-drying, involves freezing and vacuum-dehydrating CS-NPs, using cryoprotectants like trehalose or sucrose (5–10% w/v) to prevent structural damage from ice crystals. This process creates a stable lyophilized product. Cordeiro et al. found that lyophilized carboxymethyl-β-glucan/chitosan nanoparticles and covalently cross-linked CS-NPs remained stable for at least a month at 40°C. Current thermostability data for CS-NP vaccine formulations are mostly from accelerated stability studies in mice or birds, with storage times of 1–3 months at 37–60 °C. Long-term real-time stability data (6–24 months at 25 °C/60% RH) are largely missing. Ionic cross-linking offers moderate stability (30 days at 37 °C), while spray drying (3 months at 60 °C) and covalent cross-linking (1 month at 40 °C) provide better stability. The fabrication method and drying strategy significantly impact thermostability. Future research should focus on ICH-compliant real-time stability testing and optimizing cryoprotectant-chitosan ratios to develop regulatory-grade, cold-chain-independent vaccines. Applications of chitosan nanoparticles as a vaccine delivery platform Chitosan-based nanoparticles have emerged as a transformative platform in vaccine development, offering enhanced immunogenicity, targeted delivery, and improved antigen stability across a wide range of vaccine types and administration routes (Table 3). Their unique physicochemical properties, including mucoadhesiveness, biodegradability, and tunable surface charge, allow for versatile formulation strategies tailored to different antigens, delivery routes, and immunological goals. In this section, we first examine CS-NP applications categorized by antigen type, which encompass both parenteral and mucosal delivery studies, before providing a dedicated analysis of mucosal immunization routes (nasal, oral, and pulmonary) where the intrinsic biological properties of chitosan are most fully exploited. Table 3Applications of chitosan nanoparticles across vaccine modalities and delivery routesTarget pathogen/diseaseAntigen typeCS-NP formulationAdministration routeAnimal modelKey immunological findingsProtective EfficacyClinical RelevanceInactivated VaccinesPorcine epidemic diarrhea virus (PEDV)80Inactivated whole virusN-2-HACC-Al nano-adjuvantIntramuscularSwineSuperior immune activation; prolonged antigen release; depot effectHigher antibody titers; enhanced cell-mediated immunityVeterinary application; commercial potentialAvian influenza (H9N2)137Inactivated virusCS-NPsIntramuscularChickenEnhanced virus-specific antibodies; potent cellular responsesImproved immune protection (preclinical)Poultry vaccination programsNewcastle disease virus (NDV)138Inactivated virusCS/HTCC/sulfated CS-NPsIntramuscularChickenEnhanced immunogenicity; balanced immune responseImproved protection vs. alumPoultry industry applicationRift Valley Fever virus139Inactivated virusCS-NPsParenteralMouseReduced localized side effects; stable deliveryEnhanced protective immunityEmerging infectious disease controlRecombinant Subunit VaccinesHepatitis B virus (HBV)140HBsAgChitosan-heparin nanovaccine (FNC)ParenteralMouse (chronic HBV model)Enhanced DC activation; lymph node targeting; long-term immune memory90% HBsAg clearanceTherapeutic vaccine for chronic HBVHIV67Recombinant proteinsCS-based adjuvant systemsVariousMouseType I interferon induction; Th1 and cellular immune responsesBalanced immune profile addressing viral variabilityHIV vaccine developmentStreptococcus pneumoniae92PsaA proteinCS nanocapsulesIntranasalMouseImproved antigen internalization; specific T cell activationEnhanced mucosal protectionPneumococcal disease preventionHelicobacter pylori76Multi-epitope constructCS-NPsOralMouse (BALB/c)Robust gastric mucosal immunization; high sIgA levelsProtective immunity against H. pyloriGastric disease preventionSARS-CoV-263Spike protein/RBDMannose-conjugated CS-NPs (180 ± 12 nm); RBD-entrapped particles (290 ± 18 nm)IntranasalHamsterOptimal biodistribution; robust neutralizing antibodies; mucosal immunityProtection against SARS-CoV-2 challengeCOVID-19 mucosal vaccineNucleic Acid VaccinesHPV16 (E7 oncogene)57,142DNA vaccineQuaternized CS-NPsIntramuscularMouseSuperior E7-specific CD8⁺ T cell responses; enhanced IFN-γ production85% tumor protectionTherapeutic cancer vaccineSARS-CoV-255,56mRNA (spike protein)CS-modified lipid nanoparticlesInhalationMouseRobust spike-specific antibody responses; localized mucosal immunityProtection against respiratory challengeInhalable COVID-19 vaccineTrueperella pyogenes106Multivalent DNACS-DNA nanoparticlesIntramuscularMouseEnhanced immunogenicity of multivalent constructProtective immunityVeterinary applicationHepatitis B virus105pDNA (HBsAg)Novel CS-NP/DNA complexesIntranasalMouseAntibody response to HBsAg via mucosal routeInduced systemic + mucosal responsesNeedle-free HBV vaccinationMucosal Delivery ApplicationsInfluenza (SwIAV)118,152Inactivated virusCS-NPs (encapsulated vs. surface-coated)IntranasalSwineHigh titers of virus-specific antibodies; potent cellular responsesReduced viral load; improved protectionSwine influenza controlChlamydia psittaci65Inactivated elementary bodiesVCG-CS-NPsIntranasalMouseSignificant protective immunity; targeted mucosal inductive sitesProtection against respiratory challengeRespiratory pathogen controlSalmonella Enteritidis66Subunit antigensMannose-conjugated CS-NPs with adjuvantsOralBroiler chickensEnhanced systemic and mucosal immunity; DC targetingReduced Salmonella colonizationPoultry food safetyJapanese encephalitis virus (JEV)58Live attenuated virusPrecipitation-derived CS-NPs (65 ± 15 nm)IntranasalMouseSystemic seroprotection; elevated sIgAEnhanced mucosal immunity vs. subcutaneous routeJEV vaccination in endemic regionsInfluenza131Whole virusDry-powder CS nanospheresIntranasal (dry powder)RabbitRobust humoral and cellular immunityEnhanced protection in challenge modelsNeedle-free respiratory vaccinationTuberculosis92Ag85B-based fusion proteinsCS microspheres (antigen-loaded; high loading efficiency)SubcutaneousMouseLoading rates >99%; enhanced CD4⁺ T cell activation; increased IFN-γEnhanced Th1 response; protection not assessedTB subunit vaccine delivery Applications of chitosan nanoparticles across vaccine modalities and delivery routes Applications of CS-NPs based on antigen types Applications of CS-NPs in inactivated vaccines Chitosan nanoparticles have emerged as a transformative delivery platform for inactivated vaccines, primarily by providing robust antigen encapsulation and controlled release kinetics. By physically entrapping inactivated viral or bacterial particles within their polymeric matrix, CS-NPs protect sensitive antigens from enzymatic degradation, thereby maintaining structural integrity post-administration56,136. The efficiency of this encapsulation is exemplified by the N-2-hydroxypropyl trimethyl ammonium chloride chitosan-aluminum (N-2-HACC-Al) nano-adjuvant. In porcine epidemic diarrhea virus (PEDV) models, this platform demonstrated superior immune activation by facilitating the gradual release of encapsulated antigens, which prolongs the duration of immune stimulation compared to traditional formulations64. This sustained-release “depot effect” is a critical mechanism; it ensures a continuous supply of antigens to APCs, leading to significantly higher antibody titers and enhanced cell-mediated immunity137,138. Furthermore, the tunable surface charge and porosity of CS-NPs allow for optimized loading capacities for various inactivated strains, such as avian influenza and Newcastle disease viruses. Unlike traditional alum adjuvants, CS-NPs provide a more stable delivery vehicle that reduces localized side effects while simultaneously serving as a bioactive carrier139. By integrating protection with a programmed release profile, CS-NPs overcome the limitations of rapid antigen clearance, making them a versatile tool for enhancing the efficacy and safety of inactivated vaccine formulations. Applications of CS-NPs in recombinant subunit vaccines Chitosan nanoparticles significantly enhance the efficacy of recombinant subunit vaccines by transforming soluble, fragile antigens into stable, highly immunogenic particulate systems. This improvement is primarily achieved through structural protection and particulate presentation, wherein CS-NPs encapsulate purified proteins into 50–200 nm structures that mimic pathogen dimensions; this not only shields antigens from premature proteolysis but also facilitates efficient uptake by APCs77,140. Beyond antigen protection, CS-NPs have also been reported to exert immunomodulatory effects in selected HBV models, where chitosan–heparin nanovaccines fabricated by flash nanocomplexation were associated with enhanced dendritic cell activation and lymph node targeting. This approach achieved 90% HBsAg clearance and established long-term immune memory in chronic HBV mouse models140. Furthermore, some CS-based systems have been associated with type I interferon induction and Th1-skewed cellular responses in HIV vaccine studies, although these effects should be interpreted within the context of specific formulations and comparator systems67. These capabilities extend to the bacterial domain, where conjugating Streptococcus pneumoniae protein PsaA to chitosan nanocapsules has been shown to improve antigen internalization and activate specific T cells92. Collectively, these synergistic mechanisms allow CS-NPs to bridge the gap between the high safety of subunit vaccines and the requirement for robust, protective immunity. Applications of CS-NPs in nucleic acid vaccines Chitosan nanoparticles offer a specialized platform for nucleic acid delivery by leveraging their cationic nature to achieve efficient complexation, protection, and intracellular transport of negatively charged DNA and mRNA. Through electrostatic interactions, the primary amino groups of chitosan (or its quaternized derivatives like HTCC and TMC) bind to the phosphate backbone of nucleic acids, forming stable polyplexes that shield the genetic cargo from RNase and DNase degradation20,80,141,142. The intracellular delivery of nucleic acid vaccines may in part involve protonation-mediated endosomal destabilization by CS-NPs, although the relative contribution of a proton-sponge-like effect likely varies across formulations and cell systems55,56. Building on this transport mechanism, modified chitosan systems in mRNA vaccine applications have in some reports preserved mRNA secondary structure and supported higher translational efficiency. For instance, chitosan-modified lipid nanoparticles used in SARS-CoV-2 inhalable vaccines were reported to induce strong spike-specific antibody responses and localized mucosal immunity in the corresponding study55,56. Similarly, in DNA vaccine platforms, CS-NPs have been reported to enhance nuclear localization and transfection efficiency relative to naked DNA, and in HPV16 E7 models chitosan-mediated delivery was associated with stronger E7-specific CD8 + T-cell and IFN-γ responses57,142. This versatility extends to emerging gene-editing frontiers, where CS-NPs are being explored as non-viral vectors for CRISPR/Cas9 components to overcome cellular barriers for targeted genomic alterations143. Applications of CS-NPs based on mucosal immunization routes Nasal delivery systems Intranasal immunization represents a primary application for CS-NPs, leveraging their inherent mucoadhesion and permeation-enhancing capabilities to address the challenges of the nasal route. By electrostatically binding to negatively charged sialic acid residues on the nasal epithelium, CS-NPs significantly prolong the residence time of antigens, effectively overcoming rapid mucociliary clearance136,144–151 (Fig. 3). This extended contact may allow more efficient antigen translocation across the epithelial barrier to the nasal-associated lymphoid tissue, which in turn can support mucosal and systemic immune induction. The efficacy of this delivery platform is well-documented across various viral models. For instance, CS-NPs have been shown to enhance the immunogenicity of influenza vaccines (e.g., SwIAV and H9N2) by inducing high titers of virus-specific antibodies and potent cellular responses152,153. In the context of SARS-CoV-2, O-linked quaternized chitosan derivatives have successfully delivered subunit vaccines intranasally, triggering comprehensive humoral and cellular protection154. Similarly, CS-NPs loaded with inactivated Chlamydia psittaci antigens have demonstrated significant protective immunity against respiratory challenges by targeting the respiratory mucosal inductive sites65. Furthermore, the versatility of CS-NPs allows for synergistic adjuvant strategies and multivalent formulations. Combining CS-NPs with other polysaccharides, such as curdlan sulfate, has been shown to potentiate immune responses by promoting balanced Th1/Th2 profiles155. Mechanistic overview of three complementary mechanisms of chitosan nanoparticles (CS-NPs) to overcome mucosal barriers and induce protective immunity at nasal, oral, and pulmonary surfaces. A Mucoadhesion and residence-time extension. Cationic CS-NPs interact with negatively charged mucin glycoproteins via electrostatic binding and penetrate the mucus gel layer through chain entanglement. This forms a depot on the nasal/intestinal epithelium, prolonging the antigen payload’s residence time and overcoming rapid clearance and turnover. B Tight junction (TJ) modulation and paracellular flux. CS-NPs induce reversible remodeling of epithelial TJs through phosphorylation of TJ-associated proteins. This redistributes ZO-1, promotes actin reorganization, and widens the paracellular space, allowing antigens and cargo to cross the epithelial barrier. C M cell transcytosis and immune induction. In oral delivery, CS-NPs protect encapsulated antigens. At mucosal inductive sites, M cells take up CS-NPs. After transcytosis, antigens are released into the basal pocket and delivered to lymphoid tissue. Professional antigen-presenting cells capture and process the antigens, initiating immune responses. Overall, CS-NPs use a coordinated strategy of mucoadhesion, TJ opening, and M cell-targeted transcytosis to turn mucosal surfaces into gateways for vaccine-induced immunity. CS-NPs are advantageous for multivalent vaccine development due to their high encapsulation capacity, allowing efficient co-loading of diverse antigens and adjuvants. For instance, TMC-based nanoparticles can co-encapsulate multiple malaria antigens with 70-98% efficiency, preserving antigen integrity and enabling controlled release. This co-encapsulation ensures simultaneous delivery of antigens and immunostimulatory agents to the same antigen-presenting cell, crucial for effective immune priming. As a result, nanoparticles loaded with multiple virus antigens have shown enhanced pathogen-specific antibody production and increased cytokine levels compared to single-antigen formulations. Chitosan-based nanoparticles can encapsulate DNA constructs encoding multiple virulence factors, as shown by pPCFN-CpG-CS-NPs targeting four T. pyogenes antigens, which induced stronger immune responses than bivalent DNA vaccines. These capabilities make CS-NPs a versatile platform for multivalent vaccines, turning the nasal mucosa into an effective entry point for robust vaccine-induced immunity. Oral delivery systems Oral vaccination utilizing CS-NPs offers a promising non-invasive strategy by addressing the formidable chemical and enzymatic barriers of the gastrointestinal tract. CS-NPs may protect encapsulated antigens through at least two mechanisms, including pH-responsive stabilization in acidic gastric conditions and partial steric shielding against proteolytic enzymes66,156. Beyond protection, some CS-NP formulations have been designed to improve delivery to the gut-associated lymphoid tissue. For example, mannose-conjugated CS-NPs have been reported to enhance systemic and mucosal immunity against Salmonella Enteritidis, potentially in part through interactions with mannose receptors on immune cells66. Similarly, CS-NPs delivering multi-epitope Helicobacter pylori vaccines have elicited robust gastric mucosal immunization and high levels of secretory IgA (sIgA)76. The versatility of this platform is further extended through composite and multi-adjuvant systems. Incorporating materials like alginate into CS-NP formulations creates hybrid particles that further shield antigens from gastric acidity while promoting release in the near-neutral environment of the small intestine156. Furthermore, combining CS-NPs with specific adjuvants in multi-emulsion systems has been shown to significantly boost cellular and antigen-specific responses27,120. By integrating structural protection with targeted GALT activation, CS-NPs effectively bridge the gap between oral administration and potent protective immunity. Pulmonary delivery systems Pulmonary vaccine delivery via CS-NPs offers a strategic advantage for respiratory pathogens by inducing potent local immunity at the primary site of infection (Table 3). To be effective, these systems must achieve deep alveolar deposition, which is governed by the aerodynamic diameter of the particles. CS-NPs can be engineered into dry powders or micro-aggregates that facilitate bypass of the upper airways, ensuring that the encapsulated antigens reach the deep lung, a region highly enriched with alveolar macrophages and dendritic cells136,157. Upon reaching the alveolar space, CS-NPs may interact with pulmonary surfactant and, in some respiratory models, have been associated with uptake by alveolar macrophages and dendritic cells as well as transient modulation of epithelial tight junctions that could improve antigen access to underlying lymphoid tissues56,157–160. Studies in influenza and other respiratory models have confirmed that pulmonary delivery via CS-NPs results in superior mucosal IgA and systemic IgG titers compared to traditional administration, highlighting the platform’s capacity to transform the lung into a highly efficient inductive site for protective immunity152,153. Intramuscular and subcutaneous delivery systems Although mucosal vaccination has received major attention, intramuscular (IM) injection remains the dominant route in both clinical and veterinary practice. In this context, CS-NPs provide several advantages as parenteral vaccine carriers and adjuvants. Following IM administration, CS-NPs can act as a particulate depot that may prolong antigen retention at the injection site, reduce rapid antigen clearance, and support sustained recruitment and activation of APCs16,64,161. Their cationic surface may further enhance electrostatic association with negatively charged antigens and, in some systems, facilitate uptake by dendritic cells and macrophages in draining lymph nodes, thereby supporting both humoral and cellular immune responses58,162. In veterinary vaccinology, IM-delivered CS-NP formulations have outperformed conventional alum-adjuvanted systems. For example, the N-2-HACC-Al platform against PEDV induced higher antibody titers and stronger cellular immunity through sustained antigen release85. Likewise, CS-NPs and quaternized derivatives improved virus-specific IgG production and promoted balanced Th1/Th2 responses in inactivated Newcastle disease virus and H9N2 avian influenza vaccines137,138. Similar advantages were reported for chitosan-adjuvanted SARS-CoV-2 spike vaccines, which triggered prolonged recruitment of neutrophils, macrophages, and dendritic cells, consistent with depot-mediated immunostimulation161. CS-NPs also enhance nucleic acid vaccines, improving CD8 + T-cell responses, tumor protection, and overall immunogenicity after IM injection57,106,142,162. Subcutaneous delivery shows parallel benefits, including improved cross-presentation, CTL activation, mast-cell stimulation, and cytokine production16,58. Collectively, these data establish CS-NPs as versatile parenteral delivery systems for robust systemic immunity130. Comparative positioning of CS-NPs among competing nanoparticle vaccine platforms To evaluate the translational potential of CS-NPs, it is essential to compare them with the three most clinically advanced competing platforms: lipid nanoparticles (LNPs), poly(lactic-co-glycolic acid) nanoparticles (PLGA-NPs), and virus-like particles (VLPs). Lipid nanoparticles (LNPs) have achieved unprecedented regulatory success as delivery systems for mRNA vaccines, such as BNT162b2 and mRNA-1273. However, their reliance on ultra-cold storage conditions (ranging from –80 to –20 °C) and predominantly parenteral modes of administration significantly limit their deployment in resource-constrained settings and hinder the effective induction of mucosal immunity161,162. In contrast, poly(lactic-co-glycolic acid) nanoparticles (PLGA-NPs) exhibit excellent sustained-release kinetics and possess a well-established safety profile. Nonetheless, they inherently lack mucoadhesive properties, necessitate the use of organic solvents during fabrication, and induce weak mucosal secretory immunoglobulin A (sIgA) responses unless supplemented with additional adjuvants130. VLPs, like HPV and HBV vaccines, are highly immunogenic but require complex production and are thermolabile. Conversely, CS-NPs offer mucoadhesion, cGAS-STING adjuvanticity, thermostability up to 60°C, and cost-effective production from marine biomass. These features make CS-NPs ideal for needle-free mucosal vaccines, crucial for global health where cold-chain and non-invasive delivery are essential. Clinical translation status of chitosan-based vaccine systems Despite extensive preclinical evidence supporting chitosan nanoparticles (CS-NPs) as vaccine delivery systems, their clinical application is still in its early stages, with few formulations reaching human trials. A thorough review of the current clinical landscape is necessary to understand the gap between laboratory success and clinical outcomes. The most advanced chitosan-based vaccine is an intranasal influenza vaccine using chitosan glutamate as a mucosal adjuvant. A Phase I/II trial (NCT00806975) showed that this vaccine is safe and tolerable in healthy adults, inducing both local IgA and systemic HAI antibody responses. However, the mucosal immune response was weaker than the strong results seen in preclinical models, indicating a significant species-dependent translational gap. A Phase II study confirmed the safety of intranasal chitosan-adjuvanted influenza delivery but found inconsistent seroconversion rates for H1N1 and H3N2 strains, highlighting challenges in achieving adequate immunogenicity nasally. Separately, a Phase I trial of a chitosan-based diphtheria toxoid mucosal vaccine showed that intranasal administration is feasible but less effective than injections. In oncology, chitosan-based nanoparticles with tumor antigens are in early clinical trials for cancer vaccines, though detailed efficacy data are not yet available. Several key obstacles hinder the clinical application of CS-NPs. The absence of pharmaceutical-grade chitosan with consistent specifications (MW, DDA, endotoxin content) from manufacturers poses regulatory challenges for GMP production. Additionally, strong immune responses in mice do not translate to humans due to differences in mucosal immunology, particularly NALT architecture and receptor expression. Lastly, the lack of validated protection correlates for mucosal immunity complicates clinical endpoint selection and regulatory approval for mucosal CS-NP vaccines compared to traditional parenteral ones. For the majority of CS-NP vaccine candidates, empirical data on long-term stability under real-world storage conditions remain limited, posing a significant challenge for regulatory evaluation and submission. However, promising developments include the WHO’s focus on thermostable, needle-free vaccines, renewed interest in chitosan-based delivery, and advancements in microfluidic manufacturing, QbD approaches, and international standards for chitosan characterization. The COVID-19 pandemic has further accelerated the development of inhaled chitosan-based vaccines, with several candidates in advanced preclinical and early clinical stages. Key knowledge gaps and future research priorities Incomplete understanding of structure–immunomodulation relationships The key knowledge gap lies in understanding how chitosan’s physicochemical properties (like molecular weight, degree of deacetylation, and particle size) affect immunological outcomes. Although Section 5.8 discusses the impact of MW and DDA on nanoparticle performance, there is no consensus on optimal parameters, nor a predictive model for formulation design. It’s unclear why identical chitosan nanoparticle formulations sometimes trigger different immune responses or how particle structure influences inflammasome activation. High-throughput studies using well-defined chitosan libraries and multi-omics profiling of immune cells are needed to create structur activity maps for informed vaccine design. Lack of mechanistic understanding of mucosal barrier translocation While the mucoadhesive and tight junction-modulating properties of CS-NPs are well known, the exact molecular mechanisms of their movement across mucosal barriers are unclear. Key questions include: (a) the proportion of antigen transported via paracellular versus transcellular routes; (b) how the recovery speed of tight junctions post-CS-NP opening impacts mucosal administration safety; and (c) whether CS-NPs can effectively deliver antigens across the thicker intestinal mucosa using the same mechanisms as in the nasal epithelium. Advanced imaging techniques should be used to observe CS-NP movement in real time and clarify these mechanisms. Absence of long-term safety and immunological memory data Most preclinical studies reviewed focus on short-term immune responses (4–12 weeks post-immunization), with few examining long-term antibody persistence, memory B and T cell responses, or safety beyond 6 months. This is a significant gap, as the prolonged immune stimulation from CS-NPs raises concerns about chronic inflammation or granuloma formation. Additionally, the long-term effectiveness of mucosal immune memory from CS-NP vaccines is unclear, particularly whether secretory IgA responses remain protective over time. Long-term studies in large-animal models, including mucosal secretion sampling and memory cell analysis, are needed to address these issues. Limited understanding of antigen polymer interaction dynamics The molecular interactions between encapsulated antigens and the chitosan polymer matrix during formulation, storage, and release are not well understood. Key questions include: (a) whether electrostatic interactions with cationic chitosan change the structure of protein antigens, affecting their immunogenicity; (b) how the release rates of various antigens (inactivated virus, recombinant protein, mRNA, and DNA) from chitosan nanoparticles compare in physiological conditions and how these rates relate to immune responses; and (c) whether the proton sponge effect, known for nucleic acids, is equally effective for protein antigens with different molecular weights and isoelectric points. Techniques like cryo-electron microscopy, hydrogen-deuterium exchange mass spectrometry, and microfluidic dissolution assays could greatly enhance understanding in this field. Conclusion This review systematically underscores the transformative potential of CS-NPs as a next-generation vaccine delivery platform, bridging the gap between polymer chemistry and clinical vaccinology. By leveraging the tunable physicochemical properties and intrinsic biological activities of chitosan, including its antimicrobial protection, ROS-scavenging capabilities, and reported cGAS-STING/NLRP3-mediated immunomodulatory activities observed in specific preclinical models, CS-NPs provide a robust scaffold for the encapsulation and stabilized delivery of inactivated, subunit, and nucleic acid cargos. Advanced chemical modifications and precise fabrication methodologies have enabled CS-NPs to effectively overcome formidable biological barriers across both parenteral and mucosal delivery routes. In particular, CS-NPs demonstrate their most distinctive advantages in nasal, oral, and pulmonary mucosal systems, where they facilitate deep mucosal penetration, tight junction modulation, and targeted antigen-presenting cell (APC) uptake capabilities that are largely absent in competing nanoparticle platforms. Ultimately, the integration of these smart, biocompatible carriers offers a pivotal solution to global immunization challenges, paving the way for thermostable, high efficacy vaccines deliverable through multiple needle-free and minimally invasive routes including intranasal, oral, pulmonary, and microneedle based systems that can be rapidly deployed, self-administered, and distributed without cold-chain infrastructure in both routine and pandemic scenarios. Acknowledgements The authors express their gratitude to the Jiangsu Zhongmu Beikang Scientific Research Project, the members of the Swine Infectious Diseases Division, and the Jiangsu Key Laboratory for High-Tech Research and Development of Veterinary Biopharmaceuticals. This research was funded by the Jiangsu Zhongmu Beikang Scientific Research Project, grant number 2024BKYF02; the Taizhou Science and Technology Support Project (Agriculture), grant number TN202415; the project of Jiangsu Agri-animal Husbandry Vocational College, grant number NSF2026ZR04. Author contributions C.C., C.Z., S.Z., and S.C. conceived the review and prepared the original draft. Data availability Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. These authors contributed equally: Changchun Chen, Cheng Zhang. Contributor Information Shanyuan Zhu, Email: JSNM_ZSY@126.com. Shinuo Cao, Email: shinuo_cao@163.com. References Associated Data Data Availability Statement Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.